Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin

Journal of Clinical Pharmacology

Volumn 54, Issue 7, 2014, Pages 800-808

  Yan, Jing He ^a   Meyers, Dan ^a   Lee, Zachary ^a   Danis, Kate ^a   Neelakantham, Srikanth ^b   Majumdar, Tapan ^a   Rebello, Sam ^a   Sunkara, Gangadhar ^a   Chen, Jin ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

digoxin; interaction; pharmacodynamics; pharmacokinetics; warfarin

Indexed keywords

CHYLOMICRON; CYTOCHROME P450 2C9; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIGOXIN; PLASMA PROTEIN; PRADIGASTAT; TRIACYLGLYCEROL; WARFARIN; ACETIC ACID DERIVATIVE; AMINOPYRIDINE DERIVATIVE; ANTILIPEMIC AGENT; CARDIOTONIC AGENT; DGAT1 PROTEIN, HUMAN; DIACYLGLYCEROL ACYLTRANSFERASE; ENZYME INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; BLOOD SAMPLING; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENERGY BALANCE; ENZYME ACTIVITY; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; INTERNATIONAL NORMALIZED RATIO; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONOTHERAPY; NAUSEA AND VOMITING; NORMAL HUMAN; OROPHARYNX PAIN; PHARMACODYNAMICS; PROTHROMBIN TIME; SINGLE DRUG DOSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; YOUNG ADULT;

ACETATES; ADOLESCENT; ADULT; AMINOPYRIDINES; CARDIOTONIC AGENTS; COHORT STUDIES; DIACYLGLYCEROL O-ACYLTRANSFERASE; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; HYPOLIPIDEMIC AGENTS; INTERNATIONAL NORMALIZED RATIO; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS; WARFARIN; YOUNG ADULT;

EID: 84902001376     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.285     Document Type: Article

References (13)

1. Smith SJ, Cases S, Jensen DR, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet. 2000; 25: 87-90. (Pubitemid 30257043)
2. Meyers CD, Gaudet D, Tremblay K, Amer A, Chen J, Feng A,. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. J Clin Lipidol. 2012; 6 (3): 266.
3. Meyers CD, Serran-Wu M, Amer A, et al. The DGAT1 inhibitor Pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans. J Clin Lipidol. 2013; 7 (3): 285.
4. Center for Drug Evaluation and Research Drug interaction studies-study design, data analysis, implications for dosingand labeling recommendations. 2012.
5. He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharm. 2007; 47: 998-1004. (Pubitemid 47094094)
6. Nader AM, Foster DR,. Suitability of digoxin as a P-glycoprotein probe: Implications of other transporters on sensitivity and specificity. J Clin Pharm. published online: 26. OCT. 2013:DOI: 10.1002/jcph.200.
7. Digoxin prescribing information available fromPhysicians' Desk Reference Electronic Library. 2011.
8. Klotz U, Antonin KH,. 1977). Biliary excretion studies with digoxin in man. Int J Clin Pharm Biopharm. 1977; 15 (7): 332-334. (Pubitemid 8126525)
9. Lapham K, Bauman JN, Walsky RL, et al. Digoxin and tranilast identified as novel isoform-selective inhibitors of human UDP-glucuronosyltransferase 1A9 (UGT1A9) activity. Conference: 18th North American Regional ISSX Meeting Dallas, TX, United States. Conference Poster. Drug Metab Rev. 2012; 44 (S1): 82.
10. Wafarin prescribing information available fromPhysicians' Desk Reference Electronic Library. 2011.
11. Maddison J, Somogyi AA, Jensen BP, et al. The pharmacokinetics and pharmacodynamics of single dose R- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol. 2012; 75: 208-216.
12. Wright DH, Herman GA, Maes A, et al. Multiple dose of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 2009; 49: 1157-1167.
13. Rolan PE,. Plasma protein binding displacement interactions-why are they still regarded as clinically important?. Br J Clin Pharmac. 1994; 37: 125-128. (Pubitemid 24213753)